--- title: "aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29" url: "https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-27" section: "Listings" tickers: "NASDAQ:ATYR" source: "https://www.sec.gov/Archives/edgar/data/1339970/000133997026000071/atyr-20261027.htm" summary: "The split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the" --- By the aibio.space news desk. Sources - [aTyr Pharma (SEC Form 8-K)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000071/atyr-20261027.htm) - [aTyr Pharma, Inc. 10-K (2026-03-05): business](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm) - [aTyr Pharma, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) [ATYR](https://aibio.space/companies/atyr-pharma/) 2026-10-27 # aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29 Tickers [ATYR](https://aibio.space/companies/atyr-pharma/) The split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the ratio. ## Key facts - **Company**: aTyr Pharma, Inc. (NASDAQ: ATYR) - **News type**: Listings - **Primary source**: [aTyr Pharma (SEC Form 8-K)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000071/atyr-20261027.htm) *The Washington Monument and the city beyond. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* aTyr Pharma, Inc. (Nasdaq: [ATYR](https://aibio.space/companies/atyr-pharma/)) filed a Certificate of Amendment with the Delaware Secretary of State on October 27, 2026, to carry out a 1-for-40 reverse stock split of its common stock. The amendment takes effect at 5:00 p.m. Eastern Time on October 28, 2026, according to the company's Form 8-K filed the same day. Stockholders approved a series of alternate reverse split amendments at a special meeting on October 16, 2026. The board of directors approved the specific 1-for-40 ratio the same day. The 8-K does not explain why the board chose that ratio or what the company expects the split to achieve. ## The terms of the split Every 40 shares of issued and outstanding common stock will be combined into one share. Outstanding shares fall from approximately 100.5 million to approximately 2.5 million. Authorized common stock stays at 340,000,000 shares, and the par value of $0.001 per share does not change. Stock options, restricted stock units and warrants will be adjusted in proportion. Each will cover fewer shares, and the exercise price of each option and warrant will rise by the same proportion. The number of shares reserved under the equity compensation plans shrinks in the same way. No fractional shares will be issued. Holders of record who would otherwise receive a fraction of a share will have it rounded up to a whole share. The 8-K says the split affects all stockholders in the same proportion and does not change any stockholder's percentage ownership, except where a holder would end up with only a fraction of a share. The stock begins trading on a split-adjusted basis on The Nasdaq Capital Market when the market opens on October 29, 2026, under the same ticker. The new CUSIP number is 002120301. The 8-K is signed by Brandon Yaras, the company's chief financial officer. aTyr is based in San Diego, California. ## What the split leaves unchanged A reverse split changes the share count and the price per share. It does not change cash. The 8-K describes no change to the company's cash, spending or clinical plans. The annual report for 2025, filed on March 5, 2026, shows a net loss of $74.1 million, up from $64.0 million in 2024. Cash used in operations was $62.0 million in 2025, against $69.1 million in 2024. Research and development expense rose to $60.2 million from $54.4 million. Revenue was $190,000 in 2025 and $235,000 in 2024. The company's financial data show cash and cash equivalents of $16.2 million at June 30, 2026, and short-term investments of $41.3 million. The 8-K does not discuss the company's cash runway or any plan to raise money. ## The lead program and its risks The risk factors in the annual report focus on efzofitimod, a Phase 3 candidate in pulmonary sarcoidosis tested in the EFZO-FIT study. The filing says there is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis. It also says the EFZO-FIT study may not be sufficient to support FDA approval and may require additional clinical trials, and that a Phase 3 trial that misses its primary endpoint may not support an FDA pathway at all. The same risk factors cite possible manufacturing stoppages at contract manufacturers and undesirable side effects that could delay approval or limit the commercial profile of a label. The 8-K reports no trial results, so the split filing does not change what the company has shown so far. ## What comes next The split takes effect at 5:00 p.m. Eastern Time on October 28, 2026, and split-adjusted trading starts on October 29. The 8-K does not name any further milestone, financing or date for the trial program. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ATYR aTyr Pharma, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29", 2026-10-27, https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/